STAAR Surgical (STAA)
(Delayed Data from NSDQ)
$32.06 USD
-0.06 (-0.19%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $32.04 -0.02 (-0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$32.06 USD
-0.06 (-0.19%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $32.04 -0.02 (-0.06%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Are Options Traders Betting on a Big Move in STAAR (STAA) Stock?
by Zacks Equity Research
Investors need to pay close attention to STAAR (STAA) stock based on the movements in the options market lately.
Staar Surgical (STAA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 76.19% and 1.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why Growth Investors Shouldn't Overlook Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.
Is Staar Surgical (STAA) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Staar Surgical (STAA) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
3 Reasons Growth Investors Will Love Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.
What Makes Staar Surgical (STAA) a New Buy Stock
by Zacks Equity Research
Staar Surgical (STAA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SmileDirectClub (SDC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of -21.43% and 13.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Beats Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 3.57% and 2.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is Why Growth Investors Should Buy Staar Surgical (STAA) Now
by Zacks Equity Research
Staar Surgical (STAA) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts See a 42% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Staar Surgical (STAA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
3 Reasons Why Growth Investors Shouldn't Overlook Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts See a 47% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 47.1% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bear of the Day: Align Technology (ALGN)
by Jeremy Mullin
Bears continue to show big smiles when looking at this medical name.
Wall Street Analysts Think Staar Surgical (STAA) Could Surge 76%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 75.9% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Reasons Growth Investors Will Love Staar Surgical (STAA)
by Zacks Equity Research
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Q1 Earnings Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 5.50% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Staar Surgical (STAA) Q4 Earnings Top Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 18.75% and 0.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cloudflare (NET) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cloudflare's (NET) Q4 results likely to reflect benefits from its global expansion strategy, continuous addition of large amount customers and solid demand for security solutions amid the pandemic.
Twilio (TWLO) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Twilio (TWLO) Q4 top line is likely to reflect benefits from newly acquired Zipwhip and Segment. Elevated spending on product and market expansions might have weighed on the bottom line.
Fortinet (FTNT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Fortinet's (FTNT) Q4 results are likely to reflect increased demand for IT security, stellar growth in Fortinet Security Fabric, cloud and SD-WAN offerings amid the pandemic-led remote working trend.